Creative Planning Buys New Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Creative Planning bought a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,118 shares of the company’s stock, valued at approximately $28,000.

Several other large investors have also recently bought and sold shares of TSHA. Bank of New York Mellon Corp acquired a new position in Taysha Gene Therapies in the second quarter valued at $1,018,000. SG Americas Securities LLC acquired a new position in Taysha Gene Therapies in the third quarter valued at $129,000. Rhumbline Advisers acquired a new position in Taysha Gene Therapies in the second quarter valued at $413,000. Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies during the second quarter worth about $97,000. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Taysha Gene Therapies by 109.0% during the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock worth $298,000 after buying an additional 69,487 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 7.5 %

Shares of Taysha Gene Therapies stock opened at $2.21 on Thursday. Taysha Gene Therapies, Inc. has a 12-month low of $1.19 and a 12-month high of $4.32. The company has a current ratio of 5.22, a quick ratio of 5.22 and a debt-to-equity ratio of 0.35. The stock has a market cap of $452.92 million, a PE ratio of -11.15 and a beta of 0.44. The company has a 50-day moving average of $1.97 and a two-hundred day moving average of $2.39.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $3.62 million. During the same period last year, the company posted ($0.38) earnings per share. On average, research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on TSHA. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Chardan Capital reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday. Finally, Canaccord Genuity Group reduced their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $6.38.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.